GSK PLC Sponsored ADR $GSK Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC cut its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 18.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 70,787 shares of the pharmaceutical company’s stock after selling 16,404 shares during the period. TD Private Client Wealth LLC’s holdings in GSK were worth $3,471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GSK. Fisher Asset Management LLC boosted its position in GSK by 2.8% during the third quarter. Fisher Asset Management LLC now owns 32,227,615 shares of the pharmaceutical company’s stock worth $1,390,944,000 after acquiring an additional 889,210 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in GSK during the fourth quarter worth about $6,385,000. Leuthold Group LLC purchased a new position in GSK during the fourth quarter worth about $4,922,000. BI Asset Management Fondsmaeglerselskab A S raised its stake in GSK by 28.2% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock worth $4,656,000 after purchasing an additional 26,685 shares during the period. Finally, Prime Capital Investment Advisors LLC raised its stake in GSK by 182.7% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 30,188 shares of the pharmaceutical company’s stock worth $1,480,000 after purchasing an additional 19,509 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GSK. TD Cowen reaffirmed a “hold” rating on shares of GSK in a research note on Monday, February 9th. Weiss Ratings raised shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a research note on Friday, May 1st. Barclays reaffirmed an “underweight” rating on shares of GSK in a research note on Friday, February 20th. Citigroup reissued a “neutral” rating on shares of GSK in a research note on Monday, February 9th. Finally, Wall Street Zen downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, GSK has an average rating of “Reduce” and a consensus price target of $53.00.

GSK Price Performance

GSK stock opened at $50.29 on Tuesday. The company’s 50 day simple moving average is $54.23 and its 200-day simple moving average is $52.18. The company has a market capitalization of $102.05 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 2.53 and a beta of 0.38. GSK PLC Sponsored ADR has a 1 year low of $35.45 and a 1 year high of $61.69. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.52 and a current ratio of 0.79.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Friday, May 15th. GSK’s dividend payout ratio is presently 47.01%.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.